CA-TETRATE
12.4.2022 14:09:16 CEST | Business Wire | Press release
Tetrate, founded by creators and maintainers of Istio and Envoy, today announced that Istio service mesh and Envoy proxy now support the Arm® Neoverse™ platform. Arm is the leading technology provider of processor IP and its designs have enabled more than 215 billion chips. Neoverse support enables widely used open source software projects to run faster, with less energy usage and lower total cost of ownership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005425/en/
Neoverse is available on a wide range of cloud environments and for large-scale data center environments. Neoverse implementations include AWS Graviton2 processor-based Elastic Compute Cloud (Amazon EC2) instances, which offer a price/performance improvement of up to 40% over comparable x86-based instances.
“The diversity of applications is rapidly changing, and Arm is addressing the growing need for increased performance to take on compute-intensive workloads like service mesh,” said Bhumik Patel, director of ecosystem development, Infrastructure Line of Business, Arm. “By partnering with Tetrate to add Istio and Envoy support to Neoverse based platforms, we can bring better application performance, reduced energy consumption and lower TCO to customers of this industry-leading service mesh software.”
Neoverse is particularly well suited for complex workloads such as machine learning, AI, and now, service mesh . For example, AWS previewed Amazon EC2 instances powered by next-generation AWS Graviton3 processors, which will provide up to 25% better performance for compute-intensive workloads compared to current generation instances powered by Graviton2. AWS Graviton3 processors will deliver up to 2x higher floating-point performance for scientific and machine learning workloads, and will provide 50% higher memory bandwidth versus Graviton2-based instances to improve the performance of memory-intensive applications like scientific computing.
“We at Tetrate are seeing larger and more complex service mesh deployments that demand innovative solutions for meeting SLAs cost-effectively from edge to the cloud,” said Saptak Sen, vice president of Strategic Alliances at Tetrate. “We are proud to work with Arm, AWS, and the rest of the Envoy and Istio communities to help our customers in government, finance, ecommerce, and other markets make their mesh implementations more consistent, flexible, and scalable.”
Why Faster Performance is Important for Service Mesh
A service mesh is made up of microservices software instances which are created and destroyed to meet the capacity needs of an application at runtime. Each service instance is accompanied by a proxy instance, and messages between services are routed through the proxy instances.
Each message between services, or between services and the control plane, is authenticated, authorized, and encrypted/decrypted, boosting security. All of this work is compute-intensive, and encryption and decryption in particular are numerically intensive. Faster performance from the underlying hardware infrastructure can make a tremendous difference in the responsiveness of the service mesh.
Istio is the leading service mesh, and Istio software includes an extended version of the Envoy proxy. Tetrate is optimizing Istio and the Envoy proxy for performance. Neoverse supports these efforts and gives a solid boost to Istio and Envoy performance. Accelerating these software projects also yields higher performance when running Tetrate’s industry-leading service mesh management software, Tetrate Service Bridge.
How Istio Service Mesh Delivers for Government and Industry
Istio service mesh, accelerated by Arm Neoverse on multiple platforms, supports a number of benefits important to government and industry:
- Security . Service mesh performs authentication, authorization, and encryption/decryption on every communication among service instances and with the control plane, enhancing security. Neoverse speeds the necessary processing, including numerical processing for encryption and decryption.
- Agility . Service mesh supports rapid software development using continuous integration/continuous delivery (CI/CD) approaches. Neoverse provides a platform for accelerated performance, which can be managed and enhanced across software updates.
- Business continuity . With service mesh, architects can create applications that can fail over from on-premises to cloud, from one availability zone in the cloud to another, and even from one cloud to another. Neoverse support is available on all these platforms, giving applications consistent performance optimization across all deployment targets.
Download Arm-Ready Versions of Istio
Those interested can download Arm-ready versions of Istio from Tetrate Labs. Options include a FIPS version, compliant with Federal Information Processing Standard (FIPS) 140-2, Security Requirements for Cryptographic Modules. And the number of options for accessing Istio running on Neoverse across multiple platforms is large and growing. To learn more, contact Tetrate .
About Arm
Arm technology is at the heart of a computing and data revolution that is transforming the way people live and businesses operate. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 215 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners we are at the forefront of designing, securing and managing all areas of AI-enhanced connected compute from the chip to the cloud.
About Tetrate
Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Customers get consistent, baked-in observability, runtime security and traffic management in any environment. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
